Boehringer Ingelheim and Lilly have announced a new series of studies assessing the performance of empagliflozin in the treatment of chronic heart failure.
The EMPERIAL clinical trials will evaluate the effect of empagliflozin on exercise capability and heart failure symptoms in people with chronic heart failure, independent of whether they have type 2 diabetes.
“Boehringer Ingelheim and Lilly will be carrying out new studies to assess the effectiveness of empagliflozin in the treatment of chronic heart failure.“
Two phase III trials will be launched to assess the effect of 12 weeks of treatment with this drug on people with heart failure's ability to perform daily exercise, with both studies expected to finish in 2019.
The EMPERIAL trials follow on from the commencement of the EMPEROR trials in March 2017, which focus on long-term morbidity and mortality outcomes. Taken together, this represents the most comprehensive clinical trial programme ever conducted for an SGLT2 inhibitor in chronic heart failure.
Dr Jeff Emmick, vice-president of product development at Lilly Diabetes, said: "Currently, there are limited treatment options that can help improve the everyday lives of people living with chronic heart failure. We look forward to seeing whether empagliflozin can help address this unmet need."
With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.See all the latest jobs in Pharmaceutical